HUMAW (STOCKS)
Humacyte, Inc. Warrant
$0.016600
-0.017400 (-51.18%)
Prev close: $0.034000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Laura E. Niklason, MD, PhD
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- —
- Employees
- 220
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $2.02M |
| Benefits Costs and Expenses | $48.60M |
| Cost Of Revenue | $11.59M |
| Costs And Expenses | $115.90M |
| Gross Profit | -$9.58M |
| Nonoperating Income/Loss | $16.30M |
| Operating Expenses | $104.31M |
| Research and Development | $73.35M |
| Other Operating Expenses | $30.97M |
| Operating Income/Loss | -$113.89M |
| Income/Loss From Continuing Operations After Tax | -$97.59M |
| Income/Loss From Continuing Operations Before Tax | -$54.52M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$97.59M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$97.59M |
| Net Income/Loss Available To Common Stockholders, Basic | -$97.59M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.59 |
| Diluted Earnings Per Share | -$0.59 |
| Basic Average Shares | 521,243,781 |
| Diluted Average Shares | 521,243,781 |
| Assets | $110.56M |
| Current Assets | $63.60M |
| Inventory | $9.92M |
| Other Current Assets | $53.68M |
| Noncurrent Assets | $46.96M |
| Fixed Assets | $17.38M |
| Other Non-current Assets | $29.58M |
| Liabilities | $98.93M |
| Current Liabilities | $16.19M |
| Accounts Payable | $5.08M |
| Other Current Liabilities | $11.11M |
| Noncurrent Liabilities | $82.75M |
| Long-term Debt | $35.87M |
| Other Non-current Liabilities | $46.88M |
| Equity | $11.62M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $11.62M |
| Liabilities And Equity | $110.56M |
| Net Cash Flow From Operating Activities | -$101.55M |
| Net Cash Flow From Operating Activities, Continuing | -$101.55M |
| Net Cash Flow From Investing Activities | -$831.00K |
| Net Cash Flow From Investing Activities, Continuing | -$831.00K |
| Net Cash Flow From Financing Activities | $38.07M |
| Net Cash Flow From Financing Activities, Continuing | $38.07M |
| Net Cash Flow | -$64.31M |
| Net Cash Flow, Continuing | -$64.31M |
| Comprehensive Income/Loss | -$97.59M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$97.59M |
| Other Comprehensive Income/Loss | -$1.48M |